Merck SharpDohme LLC
Platinum Doublet(Merck Sharp & Dohme LLC)은 Autoimmune Disease 표적 치료제로, Autoimmune Disease; Crohn Disease 영역에서 개발·상용화 중입니다. 작용기전: targeting PI3K/AKT/mTOR pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 32% (ClinicalTrials.gov NCT02489903). 차별점: uniquely sought to evaluate N2 nodal clearance (N2NC) rates after treatment with chemotherapy and durvalumab.
Autoimmune Disease
Autoimmune Disease; Crohn Disease
Recruiting
bispecific T-cell engagers, antibody-drug conjugates, and novel combin
Deruxtecan Plus Pembrolizumab With or Without Plat
humanized antiangiogenic monoclonal antibody that stops the growth of tumour cells by inhibiting VEGF
uniquely sought to evaluate N2 nodal clearance (N2NC) rates after treatment with chemotherapy and durvalumab
targeting PI3K/AKT/mTOR pathway
immune-mediated adverse events (imAEs) were reported in 57
apoptosis, increased autophagy, and changed drug metabolism
PD-1/anti-PD-L1 mAb or cisplatin/vinorelbine+anti-PD-1/anti-PD-L1 mAb had high
resistance mechanism at progression
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Merck SharpDohme LLC
Platinum Doublet(Merck Sharp & Dohme LLC)은 Autoimmune Disease 표적 치료제로, Autoimmune Disease; Crohn Disease 영역에서 개발·상용화 중입니다. 작용기전: targeting PI3K/AKT/mTOR pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 32% (ClinicalTrials.gov NCT02489903). 차별점: uniquely sought to evaluate N2 nodal clearance (N2NC) rates after treatment with chemotherapy and durvalumab.
Autoimmune Disease
Autoimmune Disease; Crohn Disease
Recruiting
bispecific T-cell engagers, antibody-drug conjugates, and novel combin
Deruxtecan Plus Pembrolizumab With or Without Plat
humanized antiangiogenic monoclonal antibody that stops the growth of tumour cells by inhibiting VEGF
uniquely sought to evaluate N2 nodal clearance (N2NC) rates after treatment with chemotherapy and durvalumab
targeting PI3K/AKT/mTOR pathway
immune-mediated adverse events (imAEs) were reported in 57
apoptosis, increased autophagy, and changed drug metabolism
PD-1/anti-PD-L1 mAb or cisplatin/vinorelbine+anti-PD-1/anti-PD-L1 mAb had high
resistance mechanism at progression
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.